Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017

Company Has Six Presentations at AACR Highlighting Clinical and Preclinical Data BURLINGAME, Calif. , March 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab) in an oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C. The Company will also present preclinical and clinical data on CPI-444, as well as preclinical data on its investigational humanized monoclonal anti-CD73 antibody, in poster presentations. In a separate invited oral presentation, CPI-444 will be featured as a novel oral checkpoint inhibitor of adenosine mediated suppression of tumor immunity. The following are details for the six oral and poster presentations. The abstract for the oral plenary session will be available on the AACR website on March 31 at 4:30 p.m. ET . Oral Presentations Abstract #: CT119 Title: CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors Presenter: Leisha Emens , M.D., Ph.D., associate professor of oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center Session Type: Oral Plenary Presentation Date and Time: Tuesday, April 4 , 10:30 a.m.-12:45 p.m. ET Location: Ballroom C, Level 3, Washington Convention Center Title: CPI-444 – A Novel Oral Checkpoint Inhibitor of Adenosine Mediated Suppression of Tumor Immunity Presenter: Ian McCaffery , Ph.D., Corvus Pharmaceuticals Session Type: Invited Oral Presentation Date and Time: Saturday, April 1 , 3:15-5:15 p.m. ET Location: Ballroom A-B, Level 3, Washington Convention Center Poster Presentations Abstract #: 5593/ Poster #: 25 Title: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies Presenter: Stephen Willingham , Ph.D., Corvus Pharmaceuticals Presentation Date and Time: Wednesday, April 5 , 8:00 a.m- 12:00 p.m. ET Location: Convention Center, Halls A-C, Poster Section 24 Abstract #: 5598/ Poster #: 30 Title: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models Presenter: Po Y. Ho, Corvus Pharmaceuticals Presentation Date and Time: Wednesday, April 5 , 8:00 a.m- 12:00 p.m. ET Location: Convention Center, Halls A-C, Poster Section 24 Abstract #: 5579/ Poster #: 11 Title: Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor Presenter: Blake A. Scott , Johns Hopkins University School of Medicine Presentation Date and Time: Wednesday, April 5 , 8:00 a.m- 12:00 p.m. ET Location: Convention Center, Halls A-C, Poster Section 24 Abstract #: 5577/ Poster #: 9 Title: A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function Presenting Author: Emily Piccione , Ph.D., Corvus Pharmaceuticals Presentation Date and Time: Wednesday, April 5 , 8:00 a.m.-12:00 p.m. ET Location: Convention Center, Halls A-C, Poster Section 24 About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group , under a clinical trial collaboration the two companies entered into in October 2015 . For more information, visit www.corvuspharma.com . Tecentriq® is a registered trademark of Genentech. Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact: Julie Normart Pure Communications +1-415-946-1087 [email protected] Corvus Pharmaceuticals

The release as fetched from its publisher. corvuspharma.com ↗